Autoimmune Disease Testing Market Forecasts from 2023 to 2028

The autoimmune disease testing market is estimated to grow at a CAGR of 8.15% during the forecast period.

Due to the organism's aberrant response against its tissue, autoimmune disease results in the breakdown of normal immunological homeostasis. Inflammation, autoantibodies, and self-reactive T cells are typically impacted by autoimmune disorders. Potential autoimmune illnesses are difficult to diagnose since no one laboratory test can provide an accurate diagnosis of the condition. The diagnosis can aid with the treatment of autoimmune disease patients and can help with prognosis or identifying the degree of organ involvement or damage.

Market Drivers:

Growth in autoimmune disease prevalence is bolstering the market growth.

The main factor accelerating autoimmune disease testing market growth is the rising frequency of autoimmune diseases like type 1 diabetes in newborn infants together with the desire for quick diagnoses. Research and diagnostics organizations throughout the world are launching projects following governmental organizations due to the increased incidence of autoimmune illnesses and the resulting increase in healthcare costs.

Growing awareness regarding the autoimmune disease.

The prevalence of autoimmune disorders is increasing globally, and there is a growing awareness of health issues and diseases, which increases the need for diagnostics for early disease diagnosis thereby propelling the autoimmune disease testing market's expansion. The American Autoimmune Related Disease Association (AARDA), for instance, marks the month of March each year as Autoimmune Disease Awareness Month (ADAM). In February 2021, the American Kidney Fund (AKF) introduced a new patient-focused education and awareness campaign on the kidney disease lupus nephritis which is a type of autoimmune disease.

Increasing patients with rheumatoid arthritis

An autoimmune condition called rheumatoid arthritis (RA) primarily targets the synovial tissues in the joints. Most of the disease's victims are older people. The prevalence of rheumatoid arthritis among the old population has increased along with the growth of the geriatric population, which is what is driving the autoimmune disease testing market's growth. For instance, as per the World Population Prospect, in 2022 there were 771 million people worldwide who were 65 or older, and that number would rise to 994 million by 2030 and 1.6 billion by 2050.

Antinuclear antibody test to show steady growth

During the projected period, the antinuclear antibody test is anticipated to expand at the quickest rate. The autoimmune disease-causing antibodies are generated in the blood well before an individual has symptoms of the disease; this permits early identification of the condition, which lowers morbidity and mortality from the condition. The test for antinuclear antibodies is straightforward and more accurate than previous techniques. As a result, the autoimmune disease testing market growth is driven by the rising frequency of autoimmune illnesses, the need for early disease detection, and the simplicity and speed of the ANA test.

Systemic Lupus Erythematosus is expected to show significant growth.

Systemic Lupus Erythematosus is anticipated to have a significant market share over the forecast period. Multiple organs or systems are affected by systemic autoimmune disorders. Companies in the autoimmune disease testing industry have introduced tests for identifying systemic autoimmune disorders as a result of the increased frequency of systemic autoimmune diseases. For instance, Thermo Fisher Scientific Inc. (U.S.) debuted EliA RNA Pol III and EliA Rib-P assays in June 2022 after receiving FDA approval. Systemic sclerosis (SSS) and systemic lupus erythematosus (SLE) are both diagnosed using these assays. The expansion of the autoimmune disease testing market is therefore driven by the rising number of businesses releasing diagnostics for systemic autoimmune disorders.

The global immune diagnostics market is increasing

Hospitals, diagnostic facilities, and academic & research organizations make up the worldwide autoimmune disease diagnostics market. Major factors influencing the autoimmune disease diagnostics market growth include the expansion of diagnostic capabilities across all hospitals and the high level of patient choice for hospitals that offer full care, including diagnostics, procedures or treatments, and physiotherapy. Hospitals remain the preferred location for medical treatment as they offer the most cutting-edge equipment for precise diagnosis and treatment. The significant use of cutting-edge procedures, tests, and medical equipment, sponsored by public and private financing, raises the level of care offered by hospitals.

Asia Pacific is anticipated to dominate the autoimmune disease testing market

Asia-Pacific is predicted to account for a significant market share of the autoimmune disease testing market over the forecast period due to the growing prevalence of autoimmune illnesses and increased knowledge of their diagnosis. The regional market is also expanding as a result of the strategic actions undertaken by market participants, more research, and growing healthcare infrastructure.

In addition to having the greatest frequency of systemic lupus erythematosus (SLE) in China and Southeast Asia, the area already has the largest impact on chronic obstructive pulmonary disease (COPD) in the whole globe.

Key manufacturers are focusing on product innovation

The autoimmune disease testing market growth is relatively competitive. The market has sizeable market participants, and these participants are concentrating on R&D efforts and successful expansion strategies. A few diagnostic businesses recently formed strategic alliances with hospitals. To address the significant amount of patient demands across various locations, this trend is anticipated to continue throughout the forecast period. Abbott Laboratories, Biomérieux, Trinity Biotech, Bio-rad Laboratories, and Thermo Fisher Scientific are just a few of the businesses now ruling the autoimmune disease testing industry.

Market Key Developments

• In July 2022, to identify an antigen associated with the autoimmune blistering condition known as mucous membrane pemphigoid (MMP), which frequently results in painful lesions in the oral cavity, KSL Beutner Laboratories (Beutner) developed a blood test.
• In June 2022, At the 13th International Congress on Autoimmunity held in Athens, Greece, PEPperPrint GmbH presented a new biomarker set for the early detection of rheumatoid arthritis (RA).
• In May 2022, Thermofisher Scientific announced the availability of its Phadia 2500+ range of devices in the U.S. It provides dependable and unmatched high throughput for autoimmune and allergy tests.

Segmentation:

By Product Type

• Instruments
• Reagents & Consumables

By Disease Type

• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Scleroderma
• Vasculitis
• Inflammatory Bowel Disease
• Others

By Test Type

• Antinuclear Autoantibody (ANA)
• Rheumatoid Factor (RF)
• C-Reactive Protein (CRP)
• Anti-Thyroglobulin Antibody (ATA)
• Others

By End-User

• Hospitals & Clinics
• Diagnostic Centers
• Others

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others